In its first-quarter scorecard (FY ends in September), NEIMETH’s topline performance was
unimpressive as it declined by 51.31% YoY to NGN192.11mn (from NGN394.56mn in
Q1:2021). This topline performance rested solely on its pharmaceuticalsegment in the quarter
as the animal health segment recorded zero revenue. Although the management has made
no divestment announcement concerning the animal health segment, we note that no
revenue has been recorded from the segment since Q3:2021 (April- June 2021).
Kindly find the full report below
